Demonstration of a novel HIV-1 restriction phenotype from a human T cell line

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Han, Yanxing ^a   Wang, Xiaojun ^a   Dang, Ying ^a   Zheng, Yong Hui ^a  

^a Michigan State University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; ANTIRETROVIRUS AGENT; BST2 PROTEIN, HUMAN; CHLORAMPHENICOL ACETYLTRANSFERASE; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; VIF PROTEIN;

ARTICLE; CELL LINE; CONTROLLED STUDY; HETEROKARYON; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIFE CYCLE; PHENOTYPE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; T LYMPHOCYTE; VIRAL GENETICS; VIRION; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE; BIOLOGICAL MODEL; BIOSYNTHESIS; CULTURE TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-RETROVIRAL AGENTS; ANTIGENS, CD; CELL CULTURE TECHNIQUES; CELL LINE; CHLORAMPHENICOL O-ACETYLTRANSFERASE; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, VIF; HIV-1; HUMANS; MEMBRANE GLYCOPROTEINS; MODELS, BIOLOGICAL; PHENOTYPE; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; VIRUS REPLICATION;

EID: 51349101156     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002796     Document Type: Article

References (48)

1. Lilly F (1967) Susceptibility to two strains of Friend leukemia virus in mice. Science 155: 461-462.
2. Best S, Le Tissier P, Towers G, Stoye JP (1996) Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 382: 826-829.
3. Rowe WP, Humphrey JB, Lilly F (1973) A major genetic locus affecting resistance to infection with murine leukemia viruses. 3. Assignment of the Fv-1 locus to linkage group 8 of the mouse. J Exp Med 137: 850-853.
4. Kozak CA, Chakraborti A (1996) Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resistance. Virology 225: 300-305.
5. Jolicoeur P, Rassart E (1980) Effect of Fv-1 gene product on synthesis of linear and supercoiled viral DNA in cells infected with murine leukemia virus. J Virol 33: 183-195.
6. Yang WK, Kiggans JO, Yang DM, Ou CY, Tennant RW, et al. (1980) Synthesis and circularization of N- and B-tropic retroviral DNA Fv-1 permissive and restrictive mouse cells. Proc Natl Acad Sci U S A 77: 2994-2998.
7. Gao G, Guo X, Goff SP (2002) Inhibition of retroviral RNA production by ZAP, a CCCH-type zinc finger protein. Science 297: 1703-1706.
8. Guo X, Ma J, Sun J, Gao G (2007) The zinc-finger antiviral protein recruits the RNA processing exosome to degrade the target mRNA. Proc Natl Acad Sci U S A 104: 151-156.
9. Bick MJ, Carroll JW, Gao G, Goff SP, Rice CM, et al. (2003) Expression of the zinc-finger antiviral protein inhibits alphavirus replication. J Virol 77: 11555-11562.
10. Besnier C, Takeuchi Y, Towers G (2002) Restriction of lentivirus in monkeys. Proc Natl Acad Sci U S A 99: 11920-11925.
11. Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Gottlinger HG, et al. (2002) Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci U S A 99: 11914-11919.
12. Munk C, Brandt SM, Lucero G, Landau NR (2002) A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc Natl Acad Sci U S A 99: 13843-13848.
13. Owens CM, Yang PC, Gottlinger H, Sodroski J (2003) Human and simian immunodeficiency virus capsid proteins are major vital determinants of early, postentry replication blocks in simian cells. J Virol 77: 726-731.
14. Towers G, Bock M, Martin S, Takeuchi Y, Stoye JP, et al. (2000) A conserved mechanism of retrovirus restriction in mammals. Proc Natl Acad Sci U S A 97: 12295-12299.
15. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, et al. (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848-853.
16. Bour S, Strebel K (2000) HIV accessory proteins: multifunctional components of a complex system. Adv Pharmacol 48: 75-120.
17. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
18. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, et al. (2002) An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79: 285-296.
19. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, et al. (2004) Cytidine Deamination of Retroviral DNA by Diverse APOBEC Proteins. Curr Biol 14: 1392-1396.
20. Dang Y, Siew LM, Wang X, Han Y, Lampen R, et al. (2008) Human Cytidine Deaminase APOBEC3H Restricts HIV-1 Replication. J Biol Chem 283: 11606-11614.
21. Dang Y, Wang X, Esselman WJ, Zheng YH (2006) Identification of APOBEC3DE as Another Antiretroviral Factor from the Human APOBEC Family. J Virol 80: 10522-10533.
22. Doehle HP, Schafer A, Cullen BR (2005) Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339: 281-288.
23. Liddament MT, Brown WL, Schumacher AJ, Harris RS (2004) APOBEC3F Properties and Hypermutation Preferences Indicate Activity against HIV-1 In Vivo. Curr Biol 14: 1385-1391.
24. Wiegand HL, Doehle HP, Bogerd HP, Cullen BR (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. Embo J 23: 2451-2458.
25. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, et al. (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type I replication. J Virol 78: 6073-6076.
26. Kidd JM, Newman TL, Tuzun E, Kaul R, Eichler EE (2007) Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet 3: e63.
27. OhAinle M, Kerns JA, Malik HS, Emerman M (2006) Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J Virol 80: 3853-3862.
28. Dang Y, Siew LM, Zheng YH (2008) APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated. J Biol Chem 283: 13124-13131.
29. Yu X, Yu Y, Liu B, Luo K, Kong W, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302: 1056-1060.
30. Neil SJ, Eastman SW, Jouvenet N, Bieniasz PD (2006) HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog 2: e39.
31. Varthakavi V, Smith RM, Bour SP, Strebel K, Spearman P (2003) Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci U S A 100: 15154-15159.
32. Neil SJ, Zang T, Bieniasz PD (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 425-430.
33. Howell DN, Andreotti PE, Dawson JR, Cresswell P (1985) Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. J Immunol 134: 971-976.
34. Scott JE, Dawson JR (1995) MHC class I expression and transport in a calnexin-deficient cell line. J Immunol 155: 143-148.
35. Ellgaard L, Molinari M, Helenius A (1999) Setting the standards: quality control in the secretory pathway. Science 286: 1882-1888.
36. Malyguine AM, Scott JE, Dawson JR (1998) The role of calnexin in NK-target cell interaction. Immunol Lett 61: 67-71.
37. Otteken A, Moss B (1996) Calreticulin interacts with newly synthesized human immunodeficiency virus type 1 envelope glycoprotein, suggesting a chaperone function similar to that of calnexin. J Biol Chem 271: 97-103.
38. Dettenhofer M, Yu XF (2001) Characterization of the biosynthesis of human immunodeficiency virus type 1 Env from infected T-cells and the effects of glucose trimming of Env on virion infectivity. J Biol Chem 276: 5985-5991.
39. Li Y, Bergeron JJ, Luo L, Ou WJ, Thomas DY, et al. (1996) Effects of inefficient cleavage of the signal sequence of HIV-1 gp 120 on its association with calnexin, folding, and intracellular transport. Proc Natl Acad Sci U S A 93: 9606-9611.
40. Zheng YH, Yu HF, Peterlin BM (2003) Human p32 protein relieves a post-transcriptional block to HIV replication in murine cells. Nat Cell Biol 5: 611-618.
41. Madani N, Kabat D (1998) An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol 72: 10251-10255.
42. Simon JH, Gaddis NC, Fouchier RA, Malim MH (1998) Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med 4: 1397-1400.
43. Trkola A, Matthews J, Gordon C, Ketas T, Moore JP (1999) A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol 73: 8966-8974.
44. Spenlehauer C, Gordon CA, Trkola A, Moore JP (2001) A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1. Virology 280: 292-300.
45. Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W (2008) TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog 4: e16.
46. Holmes RK, Koning FA, Bishop KN, Malim MH (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 282: 2587-2595.
47. Butler SL, Hansen MS, Bushman FD (2001) A quantitative assay for HIV DNA integration in vivo. Nat Med 7: 631-634.
48. Neumann JR, Morency CA, Russian KO (1987) A novel rapid assay for chloramphenicol acetyl transferase gene expression. BIOTECHNIQUES 5: 444-447.